603233 DaShenLin Pharmaceutical Group
- 12.65
- -0.15-1.17%
DaShenLin Pharmaceutical Group News
An indicative announcement by Dashenlin Pharmaceutical Group Co., Ltd. on the “Dashen Convertible Bonds” expected to meet the revised conditions for the share conversion price
Dashenlin Pharmaceutical Group Co., Ltd. 2024 Fourth Extraordinary General Meeting of Shareholders Meeting Materials
Notice of Dashenlin Pharmaceutical Group Co., Ltd. on convening the 4th Extraordinary General Meeting of Shareholders in 2024
Announcement of Dashenlin Pharmaceutical Group Co., Ltd. on the extension of the 2020 employee stock ownership plan
Announcement of Dashenlin Pharmaceutical Group Co., Ltd. on the use of idle funds to purchase bank wealth management products
Announcement from Dashenlin Pharmaceutical Group on the resignation of the board secretary and appointment of the CFO as acting board secretary.
Legal Opinion of King & Wood Mallesons (Guangzhou) Law Firm on the Third Extraordinary General Meeting of Shareholders of Dashenlin Pharmaceutical Group Co., Ltd. in 2024, Peking.
Announcement of the resolution of the third interim shareholder meeting of Dashenlin Pharmaceutical Group Co., Ltd. in 2024.
Materials for the 3rd interim shareholder meeting of Dashenlin Pharmaceutical Group Co., Ltd. in 2024.
Announcement of Dashenlin Pharmaceutical Group Co., Ltd. regarding the progress of the lawsuit involved.
Dashenlin Pharmaceutical Group Co., Ltd.'s convertible bonds have been converted to equity, and the announcement of changes in shares.
Notice of the 3rd interim shareholder meeting of Dashenlin Pharmaceutical Group Co., Ltd. to be held in 2024.
General Manager Work Regulations (Revised July 2024)
Board of directors secretary working system (revised in July 2024).
Board of directors meeting rules (Revised in July 2024)
Announcement of the Revision of the Articles of Association and Some Corporate Governance Systems of Dashenlin Pharmaceutical Group Co., Ltd.
Trustee Management Report on the Public Issuance of Convertible Corporate Bonds by Dashenlin Pharmaceutical Group Co., Ltd. (2023)
Tracking Rating Report for Convertible Corporate Bonds of Dashenlin Pharmaceutical Group Co., Ltd. due in 2024
Announcement of the tracking rating results of convertible corporate bonds due in 2024 by Dashenlin Pharmaceutical Group Co., Ltd.
Dashenlin Pharmaceutical Group Co., Ltd.'s informative notice regarding the "Improving Efficiency to Increase Returns" action plan for the year 2024.
Analysis
Price Target
No Data
